Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 111

1.

Sipuleucel-T for the treatment of metastatic prostate cancer: promise and challenges.

Paller CJ, Antonarakis ES.

Hum Vaccin Immunother. 2012 Apr;8(4):509-19. doi: 10.4161/hv.18860. Epub 2012 Apr 1. Review.

PMID:
22336881
[PubMed - indexed for MEDLINE]
2.

Pharmaco-economic aspects of sipuleucel-T.

Simoens S.

Hum Vaccin Immunother. 2012 Apr;8(4):506-8. doi: 10.4161/hv.18334. Epub 2012 Feb 16. Review.

PMID:
22336882
[PubMed - indexed for MEDLINE]
3.

Sipuleucel-T (Provenge) autologous vaccine approved for treatment of men with asymptomatic or minimally symptomatic castrate-resistant metastatic prostate cancer.

Gardner TA, Elzey BD, Hahn NM.

Hum Vaccin Immunother. 2012 Apr;8(4):534-9. doi: 10.4161/hv.19795. Review.

PMID:
22832254
[PubMed - indexed for MEDLINE]
4.

An overview of sipuleucel-T: autologous cellular immunotherapy for prostate cancer.

Wesley JD, Whitmore J, Trager J, Sheikh N.

Hum Vaccin Immunother. 2012 Apr;8(4):520-7. doi: 10.4161/hv.18769. Epub 2012 Feb 28. Review.

PMID:
22370520
[PubMed - indexed for MEDLINE]
5.

Sipuleucel-T (Provenge): immunotherapy for metastatic prostate cancer.

Gaines KK.

Urol Nurs. 2012 Mar-Apr;32(2):95-8. No abstract available.

PMID:
22690466
[PubMed - indexed for MEDLINE]
6.

Sipuleucel-T: a vaccine for metastatic, asymptomatic, androgen-independent prostate cancer.

Patel PH, Kockler DR.

Ann Pharmacother. 2008 Jan;42(1):91-8. Epub 2007 Dec 19. Review.

PMID:
18094343
[PubMed - indexed for MEDLINE]
7.

Two years of Provenge.

Riedmann EM.

Hum Vaccin Immunother. 2012 Apr;8(4):505. doi: 10.4161/hv.20489. No abstract available.

PMID:
22832253
[PubMed - indexed for MEDLINE]
Free Article
8.

Sequencing therapy in advanced prostate cancer: focus on sipuleucel-T.

Quinn DI, Vaishampayan U, Higano CS, Lin DW, Shore ND, Beer TM.

Expert Rev Anticancer Ther. 2014 Jan;14(1):51-61. doi: 10.1586/14737140.2014.848065. Review.

PMID:
24224900
[PubMed - indexed for MEDLINE]
9.

From clinical trials to clinical practice: therapeutic cancer vaccines for the treatment of prostate cancer.

Madan RA, Aragon-Ching JB, Gulley JL, Dahut WL.

Expert Rev Vaccines. 2011 Jun;10(6):743-53. doi: 10.1586/erv.11.70. Review.

PMID:
21692697
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Development of sipuleucel-T: autologous cellular immunotherapy for the treatment of metastatic castrate resistant prostate cancer.

Sims RB.

Vaccine. 2012 Jun 19;30(29):4394-7. doi: 10.1016/j.vaccine.2011.11.058. Epub 2011 Nov 26. Review.

PMID:
22122856
[PubMed - indexed for MEDLINE]
Free Article
11.

Sipuleucel-T (Provenge®) for castration-resistant prostate cancer.

Di Lorenzo G, Ferro M, Buonerba C.

BJU Int. 2012 Jul;110(2 Pt 2):E99-104. doi: 10.1111/j.1464-410X.2011.10790.x. Epub 2011 Dec 16. Review.

PMID:
22177289
[PubMed - indexed for MEDLINE]
12.

Building on sipuleucel-T for immunologic treatment of castration-resistant prostate cancer.

Shore ND, Mantz CA, Dosoretz DE, Fernandez E, Myslicki FA, McCoy C, Finkelstein SE, Fishman MN.

Cancer Control. 2013 Jan;20(1):7-16. Review.

PMID:
23302902
[PubMed - indexed for MEDLINE]
Free Article
13.

Sipuleucel-T immunotherapy for castration-resistant prostate cancer.

Nabhan C.

N Engl J Med. 2010 Nov 11;363(20):1966-7; author reply 1968. doi: 10.1056/NEJMc1009982#SA2. No abstract available.

PMID:
21067391
[PubMed - indexed for MEDLINE]
14.

Combining immunological and androgen-directed approaches: an emerging concept in prostate cancer immunotherapy.

Antonarakis ES, Drake CG.

Curr Opin Oncol. 2012 May;24(3):258-65. doi: 10.1097/CCO.0b013e32835205a0. Review.

PMID:
22410456
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Sipuleucel-T: APC 8015, APC-8015, prostate cancer vaccine--Dendreon.

[No authors listed]

Drugs R D. 2006;7(3):197-201. Review.

PMID:
16752945
[PubMed - indexed for MEDLINE]
16.

Current vaccination strategies for prostate cancer.

Joniau S, Abrahamsson PA, Bellmunt J, Figdor C, Hamdy F, Verhagen P, Vogelzang NJ, Wirth M, Van Poppel H, Osanto S.

Eur Urol. 2012 Feb;61(2):290-306. doi: 10.1016/j.eururo.2011.09.020. Epub 2011 Oct 3. Review.

PMID:
22001436
[PubMed - indexed for MEDLINE]
17.

Integration of immunotherapy into the management of advanced prostate cancer.

Kantoff P, Higano CS.

Urol Oncol. 2012 Sep-Oct;30(5 Suppl):S41-7. doi: 10.1016/j.urolonc.2012.06.002. Review.

PMID:
23040162
[PubMed - indexed for MEDLINE]
18.

Economic evaluation of sipuleucel-T immunotherapy in castration-resistant prostate cancer.

Holko P, Kawalec P.

Expert Rev Anticancer Ther. 2014 Jan;14(1):63-73. doi: 10.1586/14737140.2014.856270. Review.

PMID:
24224852
[PubMed - indexed for MEDLINE]
19.

Cancer immunotherapy: sipuleucel-T and beyond.

Hammerstrom AE, Cauley DH, Atkinson BJ, Sharma P.

Pharmacotherapy. 2011 Aug;31(8):813-28. doi: 10.1592/phco.31.8.813. Review.

PMID:
21923608
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

The role of sipuleucel-T in therapy for castration-resistant prostate cancer: a critical analysis of the literature.

Sonpavde G, Di Lorenzo G, Higano CS, Kantoff PW, Madan R, Shore ND.

Eur Urol. 2012 Apr;61(4):639-47. doi: 10.1016/j.eururo.2011.10.027. Epub 2011 Oct 24. Review.

PMID:
22036643
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk